In 42 adults with persistent asthma in a phase 2a trial, 12 weeks of add-on dupilumab vs placebo improved lung function and asthma control but did not significantly change eosinophils, mast cells or type 2 helper cells in bronchial biopsies.
RCTn = 42
Wechsler et al. Effect of Dupilumab on Airway Inflammation in Patients With Persistent Asthma